Pfizer: Jefferies starts tracking on hold
(CercleFinance.com) - Jefferies has begun to monitor the Pfizer stock with a "hold" rating and a $43 target price (cp: $41, flat).
A lack of visibility keeps the broker from a keener stance. While PFE's long-term plans are ambitious (PFE bullish scenario: $78), Jefferies remains skeptical about their execution.
Analysts expect close to $10bn in adjusted revenue for 2030 from H1 24 launches, versus $20bn, Jefferies adds, recalling that it is below consensus on COVID revenue (close to $9-12 billion versus $13-15 billion).
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
A lack of visibility keeps the broker from a keener stance. While PFE's long-term plans are ambitious (PFE bullish scenario: $78), Jefferies remains skeptical about their execution.
Analysts expect close to $10bn in adjusted revenue for 2030 from H1 24 launches, versus $20bn, Jefferies adds, recalling that it is below consensus on COVID revenue (close to $9-12 billion versus $13-15 billion).
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.